Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1789 Neoplasms 1516 Carcinoma, Non-Small-Cell Lung 1053 Prostatic Neoplasms 965 Colorectal Neoplasms 889 Lung Neoplasms 809 Pancreatic Neoplasms 583 Carcinoma, Hepatocellular 543 Leukemia, Myeloid, Acute 540 Stomach Neoplasms 523 Ovarian Neoplasms 513 Neoplasm Metastasis 492 Multiple Myeloma 491 Recurrence 417 Melanoma 390 Squamous Cell Carcinoma of Head and Neck 374 Uterine Cervical Neoplasms 366 Brain Neoplasms 364 Head and Neck Neoplasms 355 Esophageal Neoplasms 320 Precursor Cell Lymphoblastic Leukemia-Lymphoma 313 Endometrial Neoplasms 311 Lymphoma 309 Triple Negative Breast Neoplasms 301 Glioblastoma 298 Rectal Neoplasms 284 Urinary Bladder Neoplasms 268 Sarcoma 266 Hematologic Neoplasms 266 Colonic Neoplasms 257

Interventions

trilaciclib 1 Chemoradiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Myelosuppression × Clear all

NCT06490081 2024-09-24

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Myelosuppression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡